Influence of CRP on cognitive function of patients with combined and isolated forms of atherosclerosis of cerebral and coronary vascular pools
- Authors: Bilyutin-Aslanyan R.S.1, Vasiliev A.G.1
-
Affiliations:
- St. Petersburg State Pediatric Medical University
- Issue: Vol 8, No 6 (2017)
- Pages: 80-85
- Section: Articles
- URL: https://ogarev-online.ru/pediatr/article/view/7880
- DOI: https://doi.org/10.17816/PED8680-85
- ID: 7880
Cite item
Full Text
Abstract
Cognitive impairment (CI) is a major health problem in the modern world in connection with the trend of increasing life expectancy and noticeable increase in the number of elderly people with CI and dementia. Therefore research aimed at finding and studying potential biomarkers predicting higher risk of developing CI and vascular dementia is a high priority. The study includes 207 patients (106 men and 101 women at the age of approximately 60 years. The main group includes 162 patients and there are 45 healthy individuals in the control group without clinical signs of atherosclerotic lesions, but with risk factors of their development. Patients with CPR level exceeding 10 mg/L were not included in the study. Patients with isolated and multifocal atherosclerosis of the coronary and cerebral pools have been compared by indicator of subclinical inflammation – CRP and assessment of neuropsychological test MMSE. The obtained results testified to the presence of inflammatory component in the pathogenesis of CI: the concentrations of CRP were significantly higher in patients with a low MMSE score (multifocal) than patients with higher scores of neuropsychological testing (isolated). Thus inflammation, potentially contributing to the atherosclerotic process is the basis of the relationship between high levels of CRP and cognitive impairment. At the early stages of the disease, with isolated forms of atherosclerotic vascular lesions of the heart and the head rise of CRP level can be considered the indicator of CI. With severing of the disease and the involvement of coronary and cerebral pools an increase the concentration of CRP follows. After that we have revealed a negative correlation of CRP with a marking score of cognitive function on a MMSE scale in these pathologies, i.e., the level of CRP can serve as a biochemical predictor of cognitive impairment. The obtained results indicate a significant role of CRP, its identification and monitoring can be the basis for the prevention and early diagnostics, it will also reduce the risk of severe CI, thereby maintaining higher quality of life of patients.
Full Text
##article.viewOnOriginalSite##About the authors
Robert S. Bilyutin-Aslanyan
St. Petersburg State Pediatric Medical University
Author for correspondence.
Email: bio-wolf87@mail.ru
MD, PhD student, Dept. Pathophysiology & Immunopathology
Russian Federation, Saint PetersburgAndrei G. Vasiliev
St. Petersburg State Pediatric Medical University
Email: avas7@mail.ru
MD, PhD, Dr Med Sci, Professor, Head, Dept. Pathophysiology & Immunopathology
Russian Federation, Saint PetersburgReferences
- Андросова Л.В., Михайлова Н.М., Зозуля С.А., и др. Маркеры воспаления при болезни Альцгеймера и сосудистой деменции // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2013. – Т. 113. – № 2. – С. 49–53. [Androsova LV, Mikhaylova NM, Zozulya SA, et al. Inflammatory markers in Alzheimer’s disease and vascular dementia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(2):49-53. (In Russ.)]
- Ахапкин Р.В Когнитивные нарушения при депрессивных расстройствах: анализ проблемы и перспективы решения // Современная терапия психических расстройств. – 2015. – № 4. – С. 2–7. [Akhapkin RV. Kognitivnye narusheniya pri depressivnykh rasstroystvakh: analiz problemy i perspektivy resheniya. Sovremennaya terapiya psikhicheskikh rasstroystv. 2015;(4):2-7. (In Russ.)]
- Ader R, Godbout JP, Johnson RW. Aging, neuroinflammation and behavior. J Psychoneuroimmunology. 2009.135(6):854-6.
- van Middelaar T, van Vught LA, van Charante EPM, et al. Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens. 2017; 35(10): 2095-2101. doi: 10.1097/HJH.0000000000001411.
- Bronzuoli MR, Iacomino A, Steardo L, Scuderi C. Targeting neuroinflammation in Alzheimer’s disease. J Inflamm. 2016;9:199-208. doi: 10.2147/JIR.S86958.
- Craft S, Foster TC, Landfield PW, et al. Mechanisms of age-related cognitive change and targets for intervention: inflammatory, oxidative, and metabolic processes. J Gerontol Biol Med Sci. 2012;67(7):754-759. doi: 10.1093/gerona/gls112.
- Сunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65:304-312. doi: 10.1016/j.biopsych.2008.07.024.
- Davidson S, Sujata R. Dementia and cognitive decline. A review of the evidence. 2014.
- Deary IJ, Corley J, Gow AJ, et al. Age-associated cognitive decline. British Medical Bulletin. J Dementia Gateway. 2009;92(1):135-152.
- Diyanoosh N, Rezaei O, Masafi S, et al. Relationship of Blood C — reactive protein (CRP) Level and Cognitive Deficit in Patients with Schizophrenia. International Journal of Collaborative Research on Internal Medicine & Public Health. 2012;4(10):1789-1792.
- Eikelenboom P, van Exel E, Hoozemans JM, et al. Neuroinflammation — an early event in both the history and pathogenesis of Alzheimer’s disease. Neurodegenerative Disease Medline. 2010;7:38-41. doi: 10.1159/000283480.
- Felicity BS, Snorri BR, Ian JD. Cognitive Decline and Markers of Inflammation and Hemostasis: The Edinburgh Artery Study. 2007.
- Ferri CP, Prince M, Brayne C, et al. Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117. doi: 10.1016/S0140-6736(05)67889-0.
- Fornage M, Chiang YA, O’Meara ES, et al. Biomarkers of Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health Study. Stroke. 2008;39(7):1952-1959. doi: 10.1161/STROKEAHA.107.508135.
- Gorelick PB, Ann NY. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Acad Sci. 2010;1207:155-162. doi: 10.1111/j.1749-6632.2010.05726.x.
- Hansen E, Krautwald M, Maczurek AE, et al. A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J Alzheimers Dis. 2010;19(2):451-464. doi: 10.3233/JAD-2010-1233.
- Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768-774. doi: 10.1212/WNL.0b013e3181b6bb95.
- Kravitz BA, Corrada MM, Kawas CH. High levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from The 90+ Study. J Am Geriatr Soc. 2009;57(4):641-646. doi: 10.1111/j.1532-5415.2009.02169.x.
- Lim P, Moutereau S, Simon T, et al. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]). Am J Cardiol. 2013;111:31-37. doi: 10.1016/j.amjcard.2012.08.042.
- Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean Diet, Cognitive Function, and Dementia. Epidemiology. 2013;24(4):479. doi: 10.1097/EDE.0b013e3182944410.
- Luciano M, Marioni RE, Gow AJ, et al. Reverse causation in the association between c-reactive protein and fibrinogen levels and cognitive abilities in an aging sample. Psychosomatic Medicine. 2009;71(4):404-409. doi: 10.1097/PSY.0b013e3181a24fb9.
- Mancinella A, Mancinella M, Carpinteri G, et al. Is there a relationship between high C-reactive protein (CRP) levels and dementia? J Gerontol Geriatr. 2009;49(1):185-194.
- Marioni RE, Stewart MC, Murray GD, et al. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. J Psychosomatic Medicine. 2009;71(8):901-6. doi: 10.1097/PSY.0b013e3181b1e538.
- McIntosh J. Heart Failure Patients with Cognitive Impairment “May Have Worse Outcomes”, 2015. Annual meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), American Heart Association J. About heart failure.
- Schram MT, Euser SM, de Craen AJ, et al. Systemic Markers of Inflammation and Cognitive Decline in Old Age. J Am Geriatr Soc. 2007;55(5):708-16.
- Mooijaart SP, Berbee JF, van Heemst D, et al. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med. 2006;3(6).
- Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immune as say measured fibrinogen and high sensitivity C-reactive protein levels for predicting incident cardiovascular events. J Circulation. 2006;114(5):381-387. doi: 10.1161/CIRCULATIONAHA.106.634089.
- Noble J, Manly JJ, Schupf N, et al. Association of C-reactive protein with cognitive impairment. Arch Neurol. 2010;67(1):87-92. doi: 10.1001/archneurol.2009.308.
- Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. J Pub Med PLoS One. 2008;3(1):1395. doi: 10.1371/journal.pone.0001395.
- Parra MA, Mikulan E, Trujillo N, et al. Brain Information Sharing During Visual Short-Term Memory Binding Yields a Memory Biomarker for Familial Alzheimer's Disease. Curr Alzheimer Res. 2017;14(12):1335-1347. doi: 10.2174/1567205014666170614163316.
- Prince M, Wimo A, Guerchet M, et al. World Alzheimer Report. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer’s Disease International; 2015.
- Raz N, Lindenberger U. The news of cognitive cure for age-related brain shrinkage is premature. A comment on Burgmans et al. Neuropsychology. 2010;24(2):255-257. doi: 10.1037/a0018828.
- Rosano C, Marsland AL, Gianaros PJ. Maintaining brain health by monitoring inflammatory processes: a mechanism to promote successful aging. J Aging Dis. 2012;3(1):16-33.
- Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer’s disease in blood, plasma and serum. CNS Neurosci Ther. 2009;15(4):358-374.
- Schräm MT, et al. Systemic markers of inflammation and cognitive decline in old age. J Geriatr Soc. 2007;55(5):708-16. doi: 10.1111/j.1532-5415.2007.01159.x.
- Silverman JM, Schmeidler J, Beeri MS, et al. C-reactive protein and familial risk for dementia: A phenotype for successful cognitive aging. J Neurology. 2015. doi: 10.1212/WNL.0b013e3182698c89.
- Song IU, Kim JS, Chung SW, et al. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison of Parkinson’s disease patients, disease controls and healthy individuals. J Eur Neurol. 2009;62(2):99-104. doi: 10.1159/000222780.
- Stefaniak J, O’Brien J. Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatry. 2016;87(1):21-28.
- Sundelöf J, Kilander L, Helmersson J, et al. Systemic inflammation and the risk of Alzheimer’s disease and dementia: a prospective population-based study. J Alzheimers Dis. 2010;20(2):681. doi: 10.3233/JAD-2009-1126.
- Tucker AM, Stern Y. Cognitive reserve in aging. Curr Alzheimer Res. 2011;8(4):354-360.
- van Oijen M, de Maat MP, Kardys I. Polymorphisms and haplotypes in the C-reactive protein gene and risk of dementia. J Neurobiol Aging. 2007;28(9):1361-6. doi: 10.1016/j.neurobiolaging.2006.06.015.
- Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. J Transl Med. 2015;3(10):136.
- Wotton CJ, Goldacre MJ. Age at obesity and association with subsequent dementia: record linkage study. J Postgrad Med. 2014.
Supplementary files
